CN108642167B - BAIAP2 as a target for diagnosis and treatment of rheumatoid arthritis and/or osteoarthritis - Google Patents
BAIAP2 as a target for diagnosis and treatment of rheumatoid arthritis and/or osteoarthritis Download PDFInfo
- Publication number
- CN108642167B CN108642167B CN201810291429.9A CN201810291429A CN108642167B CN 108642167 B CN108642167 B CN 108642167B CN 201810291429 A CN201810291429 A CN 201810291429A CN 108642167 B CN108642167 B CN 108642167B
- Authority
- CN
- China
- Prior art keywords
- baiap2
- gene
- rheumatoid arthritis
- osteoarthritis
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
Abstract
The invention discloses a BAIAP2 gene as a diagnosis and treatment target of rheumatoid arthritis and/or osteoarthritis. The invention can judge whether the subject suffers from the rheumatoid arthritis and/or the osteoarthritis or diagnose whether the subject is at risk of suffering from the rheumatoid arthritis and/or the osteoarthritis by detecting the content of the BAIAP2 gene and the expression product thereof in synovial tissue of the subject. In addition, the BAIAP2 gene is proved to be used as a drug target for treating rheumatoid arthritis and/or osteoarthritis by researching the proliferation index of synovial cells cultured in vitro.
Description
Technical Field
The invention relates to the field of biotechnology, in particular to application of BAIAP2 gene in diagnosis and treatment of rheumatoid arthritis and osteoarthritis.
Background
Rheumatoid arthritis is an autoimmune disease characterized by multiple joint involvement, with progressive joint destruction and deformity, often involving peripheral joints. Unclear etiology, and the involvement of extra-articular organs such as pulmonary interstitial disease and sicca syndrome are also common. Appropriate early treatment can improve joint symptoms and function, reduce mortality, and reduce complications.
A 2010 systematic review study found that the incidence of rheumatoid arthritis in north america and northern europe was estimated at 0.5% to 1.1%. The incidence in developing countries is relatively low (0.1% to 0.5%). Rheumatoid arthritis is more common in women (male and female incidence 1: 3). Onset can occur at any age, and a review cohort study calls a median onset age of 55.6 years; the number of newly diagnosed rheumatoid arthritis cases in the uk is about 20,000 per year. Therefore, each general practitioner can receive 1 new patient every 2 years.
Studies from the uk, europe and usa have all found that there is a delay in the diagnosis of rheumatoid arthritis by general practitioners. The 2009 report of the british national audition reported that before the diagnosis of rheumatoid arthritis was confirmed, patients had an average of 4 visits to their general practitioners, and 18% of patients had to visit 8 visits to confirm the diagnosis. In primary medicine, the diagnosis of early stage rheumatoid arthritis is as difficult as other skeletal muscle problems: clinical characteristic manifestations are not easily identified, inflammatory markers such as blood sedimentation and C-reactive protein have no characteristic significance, and specific marker negatives such as rheumatoid factor (serum negatives occur in 31% of patients) and anti-cyclic citrullinated peptide antibody (serum negatives occur in 33% of patients) have common serum negative manifestations.
Disability from rheumatoid arthritis can cause 28% of patients to lose work within a year. Treatment is initiated within a "window" of 3 months from onset of symptoms, which can slow disease progression. While delaying treatment increases the risk of imagewise joint destruction and death. Moreover, treatment is started after 3-6 months, so that single-drug treatment failure and drug resistance are more likely to occur.
Rheumatoid arthritis is a kind of rheumatoid arthritis in joint diseases, and some symptoms of joint swelling and pain can appear. However, many diseases are very similar to the symptoms of rheumatoid arthritis and are particularly misleading, such as osteoarthritis.
Osteoarthritis is a disease affecting human joints due to degenerative arthritis or hyperosteogeny, and is mainly caused by the fact that cartilage on the joint surface is damaged and bone tissue around the joint is proliferated due to long-term load bearing of the joints, and when osteoarthritis appears on fingers, the osteoarthritis can be misdiagnosed as rheumatoid arthritis.
Therefore, finding a method for effectively and differentially diagnosing rheumatoid arthritis and osteoarthritis in an early stage is an urgent problem to be solved, so as to avoid delaying the condition of the disease due to misdiagnosis and ensure that a patient is treated correctly.
In recent years, the study of markers for diagnosing rheumatoid arthritis or osteoarthritis at a molecular level is emerging, as in the following patent application nos.: 201310596649.X, 201580058686.2, 201380044584.6, 201310483384.2, 200610070393.9, 201510725004.0, 201510627048.X, 201510724747.6, 201510548635.X, 201510548624.1, 201510549564.5, 201510725755.2. There has not been any molecular marker for the differential diagnosis of rheumatoid arthritis and osteoarthritis, and the applicant has conducted the present study in such a context.
Disclosure of Invention
In order to solve the technical problems in the prior art, the invention aims to provide a molecular marker for early diagnosis of rheumatoid arthritis and/or osteoarthritis. The gene marker is used for distinguishing rheumatoid arthritis and osteoarthritis and has timeliness, specificity and sensitivity, so that a patient can be diagnosed in the early stage of the disease, and the cure rate is improved.
According to one aspect of the invention, the invention provides the use of a product for detecting BAIAP2 gene expression in the manufacture of a means for diagnosing rheumatoid arthritis and/or osteoarthritis.
Further, the product for detecting the expression of the BAIAP2 gene comprises a product for detecting the mRNA level of the BAIAP2 gene and/or a product for detecting the protein level of the BAIAP2 gene.
Further, the product for detecting the expression of the BAIAP2 gene comprises: products for diagnosing rheumatoid arthritis and/or osteoarthritis are obtained by detecting the expression level of the BAIAP2 gene and expression products thereof through RT-PCR, real-time quantitative PCR, immunodetection, in-situ hybridization or chip detection.
Further, the product for diagnosing rheumatoid arthritis and/or osteoarthritis by RT-PCR at least comprises a pair of primers for specifically amplifying BAIAP2 gene; the product for diagnosing rheumatoid arthritis and/or osteoarthritis by real-time quantitative PCR at least comprises a pair of primers for specifically amplifying BAIAP2 gene; the product for diagnosing rheumatoid arthritis and/or osteoarthritis by immunoassay comprises: an antibody that specifically binds to BAIAP2 protein; the product for diagnosing rheumatoid arthritis and/or osteoarthritis by in situ hybridization comprises: a probe that hybridizes to a nucleic acid sequence of a BAIAP2 gene; the product for diagnosing rheumatoid arthritis and/or osteoarthritis by using the chip comprises: protein chips and gene chips; wherein the protein chip comprises an antibody which is specifically combined with BAIAP2 protein, and the gene chip comprises a probe which is hybridized with a nucleic acid sequence of BAIAP2 gene.
The product for diagnosing rheumatoid arthritis and/or osteoarthritis by real-time quantitative PCR at least comprises a pair of primers for specifically amplifying BAIAP2 genes, wherein the primers are shown as SEQ ID NO.1 and SEQ ID NO. 2.
The product for detecting BAIAP2 gene expression can be a reagent for detecting BAIAP2 gene expression, a kit, a chip, test paper and the like containing the reagent, and can also be a high-throughput sequencing platform using the reagent.
The tool for diagnosing rheumatoid arthritis and/or osteoarthritis includes but is not limited to a chip, a kit, a test strip, or a high-throughput sequencing platform; the high-throughput sequencing platform is a special tool for diagnosing rheumatoid arthritis and/or osteoarthritis, and the construction of a gene expression profile of a person becomes very convenient and fast work with the development of a high-throughput sequencing technology. By comparing the gene expression profiles of patients with diseases and normal people, the abnormality of which gene is related to the disease can be easily analyzed. Therefore, the fact that the abnormality of the BAIAP2 gene is associated with rheumatoid arthritis and/or osteoarthritis in high-throughput sequencing also belongs to the use of the BAIAP2 gene and is also within the protection scope of the present invention.
The invention also provides a tool for diagnosing rheumatoid arthritis and/or osteoarthritis, which comprises an agent for detecting the expression of the BAIAP2 gene; the reagent comprises a primer and/or a probe for detecting BAIAP2 gene mRNA and an antibody for detecting BAIAP2 protein.
Such tools include, but are not limited to, chips, kits, test strips, or high throughput sequencing platforms.
Wherein, the chip comprises a gene chip and a protein chip; the gene chip comprises a solid phase carrier and oligonucleotide probes fixed on the solid phase carrier, wherein the oligonucleotide probes comprise oligonucleotide probes for detecting the transcription level of BAIAP2 gene and aiming at BAIAP2 gene; the protein chip comprises a solid phase carrier and a specific antibody of BAIAP2 protein fixed on the solid phase carrier; the gene chip can be used for detecting the expression levels of a plurality of genes including the BAIAP2 gene (for example, a plurality of genes related to osteoarthritis and/or rheumatoid arthritis). The protein chip can be used for detecting the expression level of a plurality of proteins including BAIAP2 protein (such as a plurality of proteins related to osteoarthritis or rheumatoid arthritis). By simultaneously detecting a plurality of markers for distinguishing rheumatoid arthritis and osteoarthritis, the diagnosis accuracy of different types of arthritis can be greatly improved.
Wherein the kit comprises a gene detection kit and a protein immunodetection kit; the gene detection kit comprises a reagent for detecting the transcription level of the BAIAP2 gene; the protein immunoassay kit comprises an antibody specific to the BAIAP2 protein. Further, the reagents include reagents required in the process of detecting the expression level of BAIAP2 gene using RT-PCR, real-time quantitative PCR, immunodetection, in situ hybridization or chip method. Preferably, the reagents comprise primers and/or probes for the BAIAP2 gene. Primers and probes which can be used for detecting the expression level of the BAIAP2 gene can be easily designed according to the nucleotide sequence information of the BAIAP2 gene.
The test paper comprises a reagent for detecting the expression of BAIAP2 gene.
The high-throughput sequencing platform comprises a reagent for detecting BAIAP2 gene expression.
The probe that hybridizes to the nucleic acid sequence of the BAIAP2 gene may be DNA, RNA, a DNA-RNA chimera, PNA, or other derivatives. The length of the probe is not limited, and any length may be used as long as specific hybridization and specific binding to the target nucleotide sequence are achieved. The length of the probe may be as short as 25, 20, 15, 13 or 10 bases in length. Also, the length of the probe can be as long as 60, 80, 100, 150, 300 base pairs or more, even for the entire gene. Since different probe lengths have different effects on hybridization efficiency and signal specificity, the length of the probe is usually at least 14 base pairs, and at most, usually not more than 30 base pairs, and the length complementary to the nucleotide sequence of interest is optimally 15 to 25 base pairs. The probe self-complementary sequence is preferably less than 4 base pairs so as not to affect hybridization efficiency.
Further, the antibody specific to the BAIAP2 protein includes monoclonal antibody and polyclonal antibody. Antibodies specific for the BAIAP2 protein include intact antibody molecules, any fragment or modification of an antibody (e.g., chimeric antibodies, scFv, Fab, F (ab') 2, Fv, etc., so long as the fragment retains the ability to bind to the BAIAP2 protein.
In a specific embodiment of the invention, the primer for detecting BAIAP2 gene mRNA comprises a primer pair shown as SEQ ID NO.1 and SEQ ID NO. 2.
The invention also provides application of the BAIAP2 gene and/or expression product thereof in preparing a medicament for treating rheumatoid arthritis and/or osteoarthritis.
Further, the medicament comprises an enhancer of the BAIAP2 gene or its expression product. The promoter comprises a component for promoting the expression of BAIAP2 gene, a component for promoting the stability of BAIAP2 gene expression product and a component for promoting the activity of BAIAP2 gene expression product.
Further, the component for promoting the expression of the BAIAP2 gene comprises an agent for promoting gene transcription, an agent for promoting gene translation and an agent for promoting the content of BAIAP2 protein.
Specifically, the components for promoting the expression of the BAIAP2 gene comprise: an agent comprising a BAIAP2 gene, a vector or host cell forming agent carrying a BAIAP2 gene, an agent comprising a BAIAP2 protein.
The accelerant of the invention can be used for supplementing the deletion or deficiency of endogenous BAIAP2 protein and treating rheumatoid arthritis and/or osteoarthritis caused by the deficiency of BAIAP2 protein by increasing the expression of BAIAP2 protein. In another aspect, may be used to promote the activity or function of BAIAP2 protein, thereby treating rheumatoid arthritis and/or osteoarthritis.
The gene-carrying vector of the present invention is a variety of vectors known in the art, such as commercially available vectors, including plasmids, cosmids, phages, viruses, and the like.
In the present invention, the term "host cell" includes prokaryotic cells and eukaryotic cells. Examples of commonly used prokaryotic host cells include E.coli, Bacillus subtilis, and the like. Commonly used eukaryotic host cells include yeast cells, insect cells, and mammalian cells. Preferably, the host cell is a eukaryotic cell, such as a CHO cell, a COS cell, or the like.
According to a further aspect of the present invention there is also provided a medicament for use in the treatment of rheumatoid arthritis and/or osteoarthritis which comprises an enhancer of the BAIAP2 gene and/or its expression product as described above.
Further, the pharmaceutical composition of the present invention further comprises a pharmaceutically acceptable carrier, such carriers include (but are not limited to): diluents, excipients such as water and the like, fillers such as starch, sucrose and the like; binders such as cellulose derivatives, alginates, gelatin, and polyvinylpyrrolidone; humectants such as glycerol; disintegrating agents such as agar, calcium carbonate and sodium bicarbonate; an absorption enhancer quaternary ammonium compound; surfactants such as cetyl alcohol; adsorption carriers such as kaolin and bentonite; lubricants such as talc, calcium and magnesium stearate, polyethylene glycol, and the like.
The mode of introducing the drug of the present invention into a tissue or cell can be classified into an in vitro mode or an in vivo mode. The in vitro method comprises introducing a drug containing a BAIAP2 gene or a drug containing a BAIAP2 protein into cells, and transplanting or returning the cells into the body. In vivo approaches include direct injection of drugs containing the BAIAP2 gene or drugs containing the BAIAP2 protein into tissues in vivo.
The medicine can also be combined with other medicines for treating rheumatoid arthritis or osteoarthritis, and the combination of a plurality of medicines can greatly improve the success rate of treatment.
In the context of the present invention, a "BAIAP 2 gene" includes polynucleotides of the BAIAP2 gene as well as any functional equivalent of the BAIAP2 gene. The BAIAP2 gene (Chromosome 17, NC _000017.11(81035147..81117432)) can be queried for related sequences in the international public nucleic acid sequence database, GeneBank.
In the context of the present invention, the BAIAP2 gene expression product comprises the mRNA of BAIAP2, the BAIAP2 protein. The BAIAP2 protein includes the BAIAP2 whole protein or a partial peptide thereof. The partial peptide contains a functional domain associated with rheumatoid arthritis or osteoarthritis.
"BAIAP 2 protein" includes BAIAP2 protein as well as any functional equivalent of BAIAP2 protein. The functional equivalents include conservative variant proteins of BAIAP2 protein, or active fragments thereof, or active derivatives thereof, allelic variants, natural mutants, induced mutants, proteins encoded by DNA capable of hybridizing to the DNA of BAIAP2 under high or low stringency conditions.
In general, it is known that modification of one or more amino acids in a protein does not affect the function of the protein. One skilled in the art will recognize that individual amino acid changes or small percentage amino acids or individual additions, deletions, insertions, substitutions to an amino acid sequence are conservative modifications, wherein a change in a protein results in a protein with a similar function. Conservative substitution tables providing functionally similar amino acids are well known in the art.
An example of a protein modified by the addition of an amino acid or amino acid residues is a fusion protein of the BAIAP2 protein. There is no limitation on the peptide or protein fused to the BAIAP2 protein, as long as the resulting fusion protein retains the biological activity of the BAIAP2 protein.
In the context of the present invention, "diagnosing rheumatoid arthritis and/or osteoarthritis" includes both determining whether a subject has suffered from rheumatoid arthritis or osteoarthritis and determining whether a subject is at risk of suffering from rheumatoid arthritis or osteoarthritis.
In the context of the present invention, "treatment" is to be divided from the change in the state of a disease and may include alleviation of the disease, complete cure of the disease, and prevention of the disease.
The invention has the advantages and beneficial effects that:
the invention discovers that the BAIAP2 gene expression is related to rheumatoid arthritis or osteoarthritis for the first time, and whether a subject has the rheumatoid arthritis or osteoarthritis or whether the subject is at risk of having the rheumatoid arthritis or osteoarthritis can be judged by detecting the BAIAP2 expression in synovial tissue of the subject, so that a clinician is guided to provide a prevention scheme or a treatment scheme for the subject.
The invention discloses a molecular marker which can diagnose both rheumatoid arthritis and osteoarthritis, and the molecular marker can distinguish normal people from arthritis patients and can also effectively distinguish rheumatoid arthritis patients from osteoarthritis patients.
The invention discloses a medicament for treating rheumatoid arthritis and osteoarthritis. One medicine has multiple purposes, enlarges the medicine indications and reduces the economic burden.
Drawings
FIG. 1 shows a statistical graph for detecting differential expression of BAIAP2 gene at the transcriptional level using QPCR;
FIG. 2 shows a statistical chart of the differential expression of BAIAP2 gene detected at protein level by Western blot;
FIG. 3 shows a statistical graph for detecting the overexpression of BAIAP2 gene at the transcriptional level using QPCR; wherein, A: osteoarthritic fibroblast-like synoviocytes; b: rheumatoid arthritis fibroblast-like synoviocytes;
FIG. 4 shows a statistical graph of the detection of the overexpression of BAIAP2 protein at the protein level using Western blot; a: osteoarthritic fibroblast-like synoviocytes; b: rheumatoid arthritis fibroblast-like synoviocytes.
Detailed Description
The present invention will be described in further detail with reference to the accompanying drawings and examples. The following examples are intended to illustrate the invention only and are not intended to limit the scope of the invention. Experimental procedures without specific conditions noted in the examples, generally following conventional conditions, such as Sambrook et al, molecular cloning: the conditions described in the laboratory Manual (New York: Cold Spring harbor laboratory Press,1989), or according to the manufacturer's recommendations.
Example 1 screening of differentially expressed genes in osteoarthritic synovial tissue, rheumatoid arthritic synovial tissue and normal synovial tissue
Synovial tissue of 5 rheumatoid arthritis patients were from rheumatoid arthritis patients in hospital orthopaedics knee replacement or synovectomy, and diagnosis of all cases met the classification standard of rheumatoid arthritis revised by the american college of rheumatology in 1987, of which 3 women, 2 men, mean age (55 ± 8) years, and mean course (12 ± 7) years. The synovial tissue of 5 osteoarthritic patients was obtained from osteoarthritic patients with orthopaedic knee replacement or synovectomy in hospitals, and the cases used met the diagnostic criteria for OA proposed by Altam, of which 2 women, 3 men, mean age (63 ± 5) years, and mean course (12 ± 8) years. 6 cases of normal synovial tissue were obtained from synovial tissue of joints of patients with trauma surgery. Clinical samples used in this study were informed and passed through the ethical committee of the hospital.
1. Tissue RNA extraction (using the Norgen RNA extraction kit)
1) Weighing about 20mg of in vitro synovial tissue sample in a clean area with less RNase interference by using a mortar containing a proper amount of liquid nitrogen, and grinding the sample into powder by using a pestle;
2) transferring the sample to a 2mL centrifuge tube without RNase;
3) adding 300 μ L lysine solution, placing in homogenizer, and grinding for 1-5 min;
4)12000g, centrifuging for 10min at 4 ℃, transferring supernatant into a new centrifuge tube with the volume of 1.5 mL;
5) adding 600 μ l RNase-Free Water, and mixing with a vortex machine;
6) adding 20 μ l protease K, bathing at 55 deg.C for 15min, and mixing with vortex;
7)14000g, centrifuging for 1min at room temperature to precipitate cell debris at the bottom of the centrifuge tube, taking supernatant and transferring the supernatant into another centrifuge tube without 1.5mL of RNase;
8) adding 450 μ l of 95% ethanol, and mixing by vortex;
RNA adsorption:
9) adding 650 μ l of lysate containing ethanol into a centrifugal column, and centrifuging for 1min at 14000 g;
10) abandoning the lower layer, and resetting the collecting pipe on the column;
11) repeating the steps from 9) to 10) according to the volume of the lysate;
12) adding 400 μ l Wash solution, 14000g, and centrifuging for 2 min;
13) abandoning the lower layer, and placing the column on a new collecting pipe;
and (3) DNase treatment:
14) adding 100 ul of Enzyme incorporation Buffer and 15 ul of DNase I, and centrifuging at 14000g for 1 min;
15) moving the solution in the collecting pipe into the column again;
16) standing at room temperature for 15 min;
RNA washing:
17) adding 400 μ l Wash solution, centrifuging at 14000g for 1min, discarding the lower layer, and placing the collection tube on the column;
18) adding 400 μ l Wash solution, centrifuging at 14000g for 2min, and discarding the collecting tube;
RNA elution:
19) the column was placed in a 1.7mL Elution tube;
20) add 30. mu.l of Elution Buffer;
21) centrifuge at 200g for 2min to allow the solution to bind well to the column, and then centrifuge at 14000g for 1 min.
2. Mass analysis of RNA samples
The concentration and purity of the RNA were determined by Nanodrop2000, RNA integrity by agarose gel electrophoresis and RIN by Agilent 2100. The total amount of RNA required for single library construction is 5 mug, the concentration is more than or equal to 200 ng/mug, and the OD260/280 is between 1.8 and 2.2.
3. Fragmented RNA
The Illumina platform is used for sequencing short sequence fragments, and the average length of mRNA can reach several kb, so random interruption is needed. The RNA can be randomly fragmented into small fragments of about 200bp by using metal ions.
4. Reverse Synthesis of cDNA
When double-strand synthesis is performed by reverse-transcribing a single-strand cDNA using mRNA as a template with a random primer by reverse transcriptase, dUTP is used instead of dTTP in dNTPs reagents so that the base in the second strand of the cDNA contains A/U/C/G.
5. Connection adapter
The double-stranded cDNA structure is sticky-ended, and is made blunt-ended by adding End Repair Mix, followed by an A base at the 3' End for ligation to a Y-shaped adaptor.
6. UNG enzyme digestion of cDNA double strand
Before PCR amplification, the second strand of cDNA was digested with UNG enzyme, so that only the first strand of cDNA was contained in the library.
7. On-machine sequencing of Illumina x-ten
Illumina x-ten sequencing platform, 2 × 150bp sequencing was performed.
8. Bioinformatics analysis
The procedure of analysis of raw data after obtaining sequencing data is as follows:
(1) carrying out trim on 5 'and 3' sections of reads by using cutadapt, wherein bases with the mass of less than 20 are removed from trim, and more than 10% of reads with N are deleted;
(2) tophat aligns to the reference genome. The reference genome version used was grch38.p7, fasta and gff files downloaded from NCBI;
(3) quantifying the expression quantity of mRNA by cuffquant and outputting the mRNA in a standardized way;
(4) the expression difference of mRNA of the control group and the disease group is compared by using a DEGseq package under the R environment. Significantly different mRNA screening conditions: p-value < 0.05.
9. Results
A total of 367 genes whose expression was different between normal persons and osteoarthritis patients, between normal persons and rheumatoid arthritis patients, and between rheumatoid arthritis patients and osteoarthritis patients were screened using the above criteria.
Example 2 Large sample validation of differentially expressed genes
Based on the results of previous high-throughput sequencing, we selected BAIAP2 gene for validation based on the size of P value, which was down-regulated in both rheumatoid arthritis and osteoarthritis patients and was more down-regulated in rheumatoid arthritis patients than in osteoarticular patients.
Detecting differential expression of BAIAP2 gene at transcriptional level
1. 100 rheumatoid arthritis synovial tissues, 100 cases of osteoarthritis synovial tissues, and 100 cases of normal synovial tissues were collected in the same manner as in example 1.
2. RNA extraction and quality testing was performed as described in the examples
3. Reverse transcription
Mu.g of total RNA was reverse transcribed with reverse transcription buffer to synthesize cDNA. A25-mu-l reaction system is adopted, 1 mu g of total RNA is taken from each sample as template RNA, and the following components are respectively added into a PCR tube: DEPC water, 5 Xreverse transcription buffer, 10mmol/L dNTP, 0.1mmol/L DTT, 30. mu. mmol/L Oligo dT, 200U/. mu. L M-MLV, template RNA. Incubate at 42 ℃ for 1h, 72 ℃ for 10min, and centrifuge briefly.
4. QPCR amplification assay
A25. mu.l reaction system was used, with 3 parallel channels per sample, and all amplification reactions were repeated three more times to ensure the reliability of the results. The following reaction system was prepared: SYBR Green polymerase chain reaction system 12.5. mu.l, forward primer (5. mu.M/. mu.l) 1. mu.l, reverse primer (5. mu.M/. mu.l) 1. mu.l, template cDNA 2.0. mu.l, 8.5. mu.l without enzyme water; amplifying a forward sequence 5'-ATGTCTCTGTCTCGCTCA-3' (SEQ ID NO.1) and a reverse sequence 5'-GGTTGAACTGCTCCATGA-3' (SEQ ID NO.2) of the BAIAP2 gene; the housekeeping gene is preferably GAPDH, and the forward primer sequence for amplifying the housekeeping gene is 5'-ATGTTCCAATATGATTCCA-3' (SEQ ID NO.3), and the reverse primer sequence is 5'-GATTTCCATTGATGACAAG-3' (SEQ ID NO. 4). All operations were performed on ice. The amplification procedure was: 95 ℃ for 5min, (95 ℃ 10s, 60 ℃ 60s) 45 cycles. By SYBR
Green is used as a fluorescent marker, PCR reaction is carried out on a Light Cycler fluorescent real-time quantitative PCR instrument, a target band is determined through melting curve analysis and electrophoresis, relative quantification is carried out by a delta CT method, and the result is shown in figure 1, compared with normal synovial tissue, the mRNA level of BAIAP2 gene in osteoarthritis synovial tissue is obviously reduced; the BAIAP2 gene mRNA levels were significantly down-regulated in rheumatoid arthritis synovial tissue compared to osteoarthritic synovial tissue, with statistical significance for the differences (. about.p < 0.05). The upper bound of the 95% confidence interval of the normal synovial tissue mean was taken as the cut-off value of the diagnostic experiment, under which condition the sensitivity of BAIAP2 for normal and osteoarthritis was 94%, specificity was 85%, and the results are shown in table 1; the sensitivity of normal humans and rheumatoid arthritis patients diagnosed with BAIAP2 was 92% and the specificity was 87%, and the results are shown in table 2. The upper bound of the 95% confidence interval of the mean value of osteoarthritic synovial tissue was used as cut-off value in the diagnostic test, under which condition BAIAP2 was used to diagnose osteoarthritis and rheumatoid arthritis with a sensitivity of 91% and a specificity of 89%, and the results are shown in table 3.
TABLE 1 differentiation of Normal persons from osteoarthritis patients
TABLE 2 differentiation of Normal persons from rheumatoid arthritis patients
TABLE 3 osteoarthritis patients are distinguished from rheumatoid arthritis patients
Second, detection of differential expression of BAIAP2 gene at protein level
1. Tissue protein extraction
(1) Weighing 50mg of tissue, and fully grinding the tissue by using liquid nitrogen;
(2) adding 500 mul of mixed working solution (RIPA lysate: PMSF 100:1) into each sample, and fully shaking;
(3) centrifuging at 13000rpm/min for 10min, and subpackaging the supernatant at-80 deg.C for storage.
2. Western blot detection
And (3) carrying out SDS-PAGE electrophoresis on the extracted protein quantitatively, and then carrying out membrane transfer, sealing, primary antibody incubation, secondary antibody incubation and color development.
3. Statistical treatment
The grey value of the protein band is analyzed by using Image J software, and the grey value of the BAIAP2 protein band is normalized by taking beta-actin as an internal reference. The results were expressed as mean ± sd, statistically analyzed using SPSS13.0 statistical software, and the difference between the two was considered statistically significant when P <0.05 using the t-test.
4. Results
The results are shown in figure 2, the BAIAP2 protein content in osteoarthritic synovial tissue is significantly reduced compared to normal synovial tissue; BAIAP2 protein was significantly reduced in rheumatoid arthritis synovial tissue compared to osteoarthritic synovial tissue, with statistical significance for the differences (. about.p < 0.05).
Example 3 construction of a BAIAP2 Gene expression plasmid
1. Construction of BAIAP2 Gene expression vector
The amplification primers were designed based on the coding sequence of the BAIAP2 gene (shown in SEQ ID NO. 5). The coding sequence of the full-length BAIAP2 gene was amplified from a cDNA library of adult fetal brain (Clontech, cat # 638831), the above cDNA sequence was double digested with restriction enzymes BamHI and XhoI, inserted into the eukaryotic cell expression vector pcDNA3.1 double digested with restriction enzymes BamHI and XhoI, and the resulting recombinant vector pcDNA3.1-BAIAP2 was ligated for subsequent experiments.
2. Synovial tissue cell in vitro culture
Washing aseptically obtained synovium tissue of rheumatoid arthritis and osteoarthritis with PBS, repeatedly shearing with aseptic surgical scissors to obtain tissue blocks of about 1mm x 1mm x 1mm, adding collagenase II (0.5mg/ml) at 37 deg.C, digesting for 2 hr, filtering with 200 mesh gauze, centrifuging to remove supernatant, resuspending cells in DMEM culture solution, standing at 37 deg.C and 5% CO2Culturing in a cell culture box. When the cells grew into spindle-shaped and flaked, subculture was performed. After the cells are transmitted to 3 rd generation, FITC labeled mouse anti-human CD3, CD14, CD19 and PE labeled mouse anti-human CD11b are added for labeling, and flow cytometry detection and identification are carried out. The cells that were negative for all 4 markers described above were Fibroblast-like Synoviocytes (FLS) used in this study.
3. Transfection
The prepared fibroblast-like synoviocytes were divided into two groups, a control group (transfected pcDNA3.1 empty vector) and a BAIAP2 overexpression group (transfected pcDNA3.1-BAIAP 2). Transfection of the vector was performed using liposome 2000, and the specific transfection method was performed as indicated in the specification. The working concentrations of pcDNA3.1 empty vector and pcDNA3.1-BAIAP2 were 0.5. mu.g/ml.
4. QPCR detection
4.1 extraction of cellular Total RNA Using conventional methods.
4.2 reverse transcription and QPCR procedures were the same as in example 2.
4.3 results
As shown in FIG. 3, the mRNA level of BAIAP2 was significantly up-regulated in the pcDNA3.1-BAIAP 2-transfected cells compared to the pcDNA3.1 empty vector-transfected cells, the difference being statistically significant (P <0.05)
5. Western detection
5.1 extraction of Total cellular protein
And (3) extracting the total protein of the cells by taking the fibroblast-like synoviocytes with good log-phase growth, and extracting the protein according to the instruction of an EpiQuik whole-cell extraction kit.
5.2Western blot detection
The procedure is as in example 2.
5.3 results
As shown in FIG. 4, the protein level of BAIAP2 was significantly up-regulated in cells transfected with pcDNA3.1-BAIAP2 compared to cells transfected with pcDNA3.1 empty vector, with a difference of statistical significance (P < 0.05).
Example 4 Effect of BAIAP2 Gene overexpression on fibroblast-like synoviocytes proliferation
1. Step (ii) of
At 2 × 105The cells were inoculated in 96-well cell culture plates at a density of one ml, and after the cells were attached to the walls, cell transfection was performed according to the method of example 3, each experimental group was designed to have three wells, each 100. mu.l, placed at 37 ℃ in 5% CO2After 48h of transfection, 10. mu.l of CK-8 solution was added to each well of the wells to be tested, and the cells were incubated in the incubator for 1h to measure the absorbance (OD) of each well at 450 nm.
2. Statistical method
The experiments were performed in 3 replicates, the data were expressed as mean ± sd, and the statistical analysis was performed using SPSS13.0 statistical software, and the difference between BAIAP2 gene overexpression group and control group was considered statistically significant when P <0.05 using t-test.
3. Results
The results are shown in tables 4 and 5, that the proliferation of the pcDNA3.1-BAIAP2 transfected cells was significantly slower than that of the cells transfected with the pcDNA3.1 empty vector, the difference being statistically significant (P < 0.05).
TABLE 4 determination of OD values for osteoarthritis fibroblast-like synoviocytes
| Experimental group | OD value (optical Density) |
| pcDNA3.1 | 0.1539±0.004 |
| pcDNA3.1-BAIAP2 | 0.0602±0.002 |
TABLE 5 determination of OD values of synovial cells of rheumatoid arthritis
| Experimental group | OD value (optical Density) |
| pcDNA3.1 | 0.1578±0.002 |
| pcDNA3.1-BAIAP2 | 0.0593±0.001 |
The above description of the embodiments is only intended to illustrate the method of the invention and its core idea. It should be noted that, for those skilled in the art, without departing from the principle of the present invention, several improvements and modifications can be made to the present invention, and these improvements and modifications will also fall into the protection scope of the claims of the present invention.
Sequence listing
<110> Beijing, the deep biometric information technology GmbH
<120> BAIAP2 as a diagnostic target for rheumatoid arthritis and/or osteoarthritis
<160>5
<170>SIPOSequenceListing 1.0
<210>1
<211>18
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>1
atgtctctgt ctcgctca 18
<210>2
<211>18
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>2
ggttgaactg ctccatga 18
<210>3
<211>19
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>3
atgttccaat atgattcca 19
<210>4
<211>19
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>4
gatttccatt gatgacaag 19
<210>5
<211>1605
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>5
atgtctctgt ctcgctcaga ggagatgcac cggctcacgg aaaatgtcta taagaccatc 60
atggagcagt tcaaccctag cctccggaac ttcatcgcca tggggaagaa ttacgagaag 120
gcactggcag gtgtgacgta tgcagccaaa ggctactttg acgccctggt gaagatgggg 180
gagctggcca gcgagagcca gggctccaaa gaactcggag acgttctctt ccagatggct 240
gaagtccaca ggcagatcca gaatcagctg gaagaaatgc tgaagtcttt tcacaacgag 300
ctgcttacgc agctggagca gaaggtggag ctggactcca ggtatctgag tgctgcgctg 360
aagaaatacc agactgagca aaggagcaaa ggcgacgccc tggacaagtg tcaggctgag 420
ctgaagaagc ttcggaagaa gagccagggc agcaagaatc ctcagaagta ctcggacaag 480
gagctgcagt acatcgacgc catcagcaac aagcagggcg agctggagaa ttacgtgtcc 540
gacggctaca agaccgcact gacagaggag cgcaggcgct tctgcttcct ggtggagaag 600
cagtgcgccg tggccaagaa ctccgcggcc taccactcca agggcaagga gctgctggcg 660
cagaagctgc cgctgtggca acaggcctgt gccgacccca gcaagatccc ggagcgcgcg 720
gtgcagctca tgcagcaggt ggccagcaac ggcgccaccc tccccagcgc cctgtcggcc 780
tccaagtcca acctggtcat ttccgacccc attccggggg ccaagcccct gccggtgccc 840
cccgagctgg caccgttcgt ggggcggatg tctgcccagg agagcacacc catcatgaac 900
ggcgtcacag gcccggatgg cgaggactac agcccgtggg ctgaccgcaa ggctgcccag 960
cccaaatccc tgtctcctcc gcagtctcag agcaagctca gcgactccta ctccaacaca 1020
ctccccgtgc gcaagagcgt gaccccaaaa aacagctatg ccaccaccga gaacaagact 1080
ctgcctcgct cgagctccat ggcagccggc ctggagcgca atggccgtat gcgggtgaag 1140
gccatcttct cccacgctgc tggggacaac agcaccctcc tgagcttcaa ggagggtgac 1200
ctcattaccc tgctggtgcc tgaggcccgc gatggctggc actacggaga gagtgagaag 1260
accaagatgc ggggctggtt tcccttctcc tacacccggg tcttggacag cgatggcagt 1320
gacaggctgc acatgagcct gcagcaaggg aagagcagca gcacgggcaa cctcctggac 1380
aaggacgacc tggccatccc accccccgat tacggcgccg cctcccgggc cttccccgcc 1440
cagacggcca gcggcttcaa gcagaggccc tacagtgtgg ccgtgcccgc cttctcccag 1500
ggcctggatg actatggagc gcggtccatg agcaggaatc cctttgccca cgtccagctg 1560
aagccgacag tgaccaacga caggtctgcc cccctcctca gctga 1605
Claims (3)
1. Use of an agent promoting BAIAP2 gene expression in the manufacture of a medicament for the treatment of osteoarthritis.
2. The use of claim 1, wherein the agent that promotes BAIAP2 gene expression comprises an agent comprising a BAIAP2 gene, a vector carrying a BAIAP2 gene, or a host cell forming agent.
Use of BAIAP2 protein for the manufacture of a medicament for the treatment of osteoarthritis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810291429.9A CN108642167B (en) | 2018-03-30 | 2018-03-30 | BAIAP2 as a target for diagnosis and treatment of rheumatoid arthritis and/or osteoarthritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810291429.9A CN108642167B (en) | 2018-03-30 | 2018-03-30 | BAIAP2 as a target for diagnosis and treatment of rheumatoid arthritis and/or osteoarthritis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108642167A CN108642167A (en) | 2018-10-12 |
| CN108642167B true CN108642167B (en) | 2020-08-25 |
Family
ID=63745138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810291429.9A Active CN108642167B (en) | 2018-03-30 | 2018-03-30 | BAIAP2 as a target for diagnosis and treatment of rheumatoid arthritis and/or osteoarthritis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108642167B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110066866B (en) * | 2019-01-17 | 2021-12-07 | 浙江大学 | Biomarkers of osteoarthritis fourth subtype and uses |
| CN116425854B (en) * | 2022-08-02 | 2024-04-05 | 河北医科大学 | Biomarker for anxiety and depression related diseases, kit and medicament |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100273671A1 (en) * | 2007-03-01 | 2010-10-28 | Universite Catholique De Louvain | Method for the determination and the classification of rheumatic conditions |
| CN106795557A (en) * | 2014-06-02 | 2017-05-31 | 瓦利保健系统公司 | For the method and system of pulmonary cancer diagnosis |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070026424A1 (en) * | 2005-04-15 | 2007-02-01 | Powell Charles A | Gene profiles correlating with histology and prognosis |
| KR20170001912A (en) * | 2015-06-26 | 2017-01-05 | 기초과학연구원 | Pharmaceutical composition for prevention and treatment of mental disease with enhanced nmdar function |
-
2018
- 2018-03-30 CN CN201810291429.9A patent/CN108642167B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100273671A1 (en) * | 2007-03-01 | 2010-10-28 | Universite Catholique De Louvain | Method for the determination and the classification of rheumatic conditions |
| CN106795557A (en) * | 2014-06-02 | 2017-05-31 | 瓦利保健系统公司 | For the method and system of pulmonary cancer diagnosis |
Non-Patent Citations (5)
| Title |
|---|
| BAI1-Associated Protein 2-Like 1 (BAIAP2L1) Is a Potential Biomarker in Ovarian Cancer;Chao A等;《PLoS One》;20150729;第10卷(第7期);第1-13页 * |
| BAIAP2 is related to emotional modulation of human memory strength;Luksys G等;《PLoS One》;20140131;第9卷(第1期);第1-10页 * |
| BAIAP2基因多态与儿童注意缺陷多动障碍共患学习困难的关联分析;李泽华等;《中国心理卫生杂志》;20120610;第26卷(第6期);第429-434页 * |
| Cortactin autoantibodies in myasthenia gravis.;Gallardo E等;《Autoimmun Rev》;20141031;第13卷(第10期);第1003-1007页 * |
| 基因芯片技术研究清络痛痹颗粒对类风湿关节炎患者成纤维样滑膜细胞基因表达的影响;黄艳等;《中华中医药杂志》;20140930;第29卷(第9期);第2945页左栏第1段，第2947页右栏第1段，表3 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108642167A (en) | 2018-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008524986A (en) | Genetic changes useful for predicting malignant tumor response to taxane-based drug therapy | |
| CN108642167B (en) | BAIAP2 as a target for diagnosis and treatment of rheumatoid arthritis and/or osteoarthritis | |
| CN108103186B (en) | Molecular markers for diagnosis of rheumatoid arthritis and osteoarthritis | |
| CN108611409B (en) | Biomarker for diagnosis and treatment of rheumatoid arthritis and osteoarthritis | |
| CN105296623B (en) | A kind of molecular marker of diagnosis and treatment osteoarthritis | |
| CN108559772B (en) | MARCH1 gene as diagnosis and treatment marker for rheumatoid arthritis and osteoarthritis | |
| CN108359726B (en) | Application of CORO2B as molecular diagnosis and treatment marker | |
| CN108384846B (en) | Application of C11orf95 gene and expression product thereof in diagnosis and treatment of rheumatoid arthritis and osteoarthritis | |
| CN111378668B (en) | Non-coding RNA as diagnosis and treatment marker of osteoporosis | |
| Christiano et al. | Compound heterozygosity for nonsense and missense mutations in the LAMB3 gene in nonlethal junctional epidermolysis bullosa | |
| CN105132550A (en) | Application of MUC21 gene expression detection reagent in preparation of osteoarthritis diagnosis and treatment products | |
| US20040029192A1 (en) | Compositions and methods for the diagnosis and treatment of kidney disease | |
| CN105132574B (en) | Osteoarthritis diagnosis and treatment marker and its application | |
| CN108486245B (en) | WFS1 as a novel molecular marker | |
| CN108642168B (en) | Diagnosis and treatment of rheumatoid arthritis and osteoarthritis based on SPAST gene | |
| CN107164507A (en) | The diagnostic tool of postmenopausal women's primary osteoporosis | |
| CN110577994B (en) | Product for non-invasive diagnosis of male osteoporosis | |
| CN110577995B (en) | Diagnostic marker for male osteoporosis | |
| Thorson et al. | Identification of SYT-SSX transcripts from synovial sarcomas using RT-multiplex PCR and capillary electrophoresis | |
| KR20210134551A (en) | Biomarkers for predicting the recurrence possibility and survival prognosis of papillary renal cell carcinoma and uses thereof | |
| JP5565784B2 (en) | Use of myelin basic protein as a novel genetic factor in rheumatoid arthritis | |
| KR101818672B1 (en) | Diagnosis composition of atopic dermatitis and diagnosis method of atopic dermatitis using the same | |
| JP2003204790A (en) | Disease-sensitive gene of chronic rheumatoid arthritis and use thereof | |
| US20080167326A1 (en) | Method For Assessing the Predisposition and/or Susceptibility to Copd by Analysing Fgf-Bp1 | |
| CN112877421B (en) | Scar-related biomarker and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: Room 1210, Building 3, Ronghua Xintai Building, 10 Ronghua South Road, Yizhuang Economic and Technological Development Zone, Daxing District, Beijing Applicant after: Beijing Yang Shen biology information technology company limited Address before: 100080 Beijing city Haidian District Shanyuan Street No. 1 cubic court building room 3103 Applicant before: Beijing Yang Shen biology information technology company limited |
|
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20200407 Address after: Room 2503, Qianshan building, building D2, Qingdao International Innovation Park Phase II, No. 1, Keyuan Weiyi Road, Laoshan District, Qingdao, Shandong Province Applicant after: Qingdao Yangshen biomedical Co., Ltd Address before: Room 1210, Building 3, Ronghua Xintai Building, 10 Ronghua South Road, Yizhuang Economic and Technological Development Zone, Daxing District, Beijing Applicant before: BEIJING MEDINTELL BIOMED INFORMATION TECHNOLOGY Co.,Ltd. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |